Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Minority Interest (2023 - 2025)

Historic Minority Interest for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Q2 2025 value amounting to $9.1 million.

  • Zhengye Biotechnology Holding's Minority Interest changed N/A to $9.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $9.1 million, marking a year-over-year change of. This contributed to the annual value of $9.5 million for FY2024, which is 154.89% up from last year.
  • Per Zhengye Biotechnology Holding's latest filing, its Minority Interest stood at $9.1 million for Q2 2025.
  • In the past 5 years, Zhengye Biotechnology Holding's Minority Interest ranged from a high of $9.5 million in Q4 2024 and a low of $9.1 million during Q2 2025
  • Its 3-year average for Minority Interest is $9.3 million, with a median of $9.2 million in 2023.
  • Data for Zhengye Biotechnology Holding's Minority Interest shows a peak YoY increase of 349.45% (in 2024) and a maximum YoY decrease of 349.45% (in 2024) over the last 5 years.
  • Over the past 3 years, Zhengye Biotechnology Holding's Minority Interest (Quarter) stood at $9.2 million in 2023, then grew by 3.49% to $9.5 million in 2024, then decreased by 4.18% to $9.1 million in 2025.
  • Its Minority Interest was $9.1 million in Q2 2025, compared to $9.5 million in Q4 2024 and $9.2 million in Q4 2023.